godlords11 karma2021-04-07 21:12:05 UTC
What kind of tax implications should the pharmaceutical/biotechnology industries expect from Biden? R&D credits? Do you see any significant regulatory pricing pressures materializing? Not sure if this is anyone’s real expertise, but is there any expectation for a more stringent, slower FDA?
View HistoryShare Link
godlords2 karma2021-04-07 22:11:44 UTC
Thank you for your time and your expertise. Yeah, FDA has been moving impressively fast and been really open to utilizing fast track/orphan designation, I was afraid we might regress from that.
Copyright © 2014 BestofAMA.com, All rights reserved.
reddit has not approved or endorsed BestofAMA, reddit design elements are trademarks of reddit inc.